Table 1.
Subject characteristics for stretch reflex wind-up
| Subj. | Age (years) | Duration of SCI (months) | Neuro- logical level | ASIA classifi- cation | Anti-spasticity medications |
|---|---|---|---|---|---|
| 1 | 40 | 42 | C6 | A | 110 mg baclofen |
| 2 | 35 | 136 | T6 | A | None |
| 3 | 47 | 24 | T10 | A | None |
| 4 | 30 | 48 | C8 | C | 160 mg baclofen |
| 5 | 41 | 324 | C2 | D | 60 mg baclofen |
| 6 | 49 | 48 | C7 | B | 120 mg baclofen |
| 7 | 26 | 46 | T2–4 | C | None |
| 8 | 44 | 36 | C6 | D | None |
| 9 | 25 | 14 | C8 | C | None |
| 10 | 36 | 16 | T4 | A | None |
| 11 | 25 | 70 | C5 | A | 160 mg baclofen |
| 12 | 34 | 65 | T4 | A | None |
| 13 | 32 | 62 | C4–5 | C | None |
| 14 | 39 | 204 | T7 | A | 100 mg baclofen |
Subject characteristics for assessment of stretch reflex wind-up are provided, including age, duration of spinal cord injury (SCI), neurological level and classification, as determined by the American Spinal Injury Association (ASIA; Maynard et al. 1997), and total daily dose of anti-spastic medication (specifically baclofen).